The Interactions of Parasite Calreticulin With Initial Complement Components: Consequences in Immunity and Virulence
Artículo
Open/ Download
Access note
Acceso Abierto
Publication date
2020Metadata
Show full item record
Cómo citar
Ramírez Toloza, Galia
Cómo citar
The Interactions of Parasite Calreticulin With Initial Complement Components: Consequences in Immunity and Virulence
Author
Abstract
Because of its capacity to increase a physiologic inflammatory response, to stimulate phagocytosis, to promote cell lysis and to enhance pathogen immunogenicity, the complement system is a crucial component of both the innate and adaptive immune responses. However, many infectious agents resist the activation of this system by expressing or secreting proteins with a role as complement regulatory, mainly inhibitory, proteins.Trypanosoma cruzi, the causal agent of Chagas disease, a reemerging microbial ailment, possesses several virulence factors with capacity to inhibit complement at different stages of activation.T. cruzicalreticulin (TcCalr) is a highly-conserved, endoplasmic reticulum-resident chaperone that the parasite translocates to the extracellular environment, where it exerts a variety of functions. Among these functions, TcCalr binds C1, MBL and ficolins, thus inhibiting the classical and lectin pathways of complement at their earliest stages of activation. Moreover, the TcCalr/C1 interaction also mediates infectivity by mimicking a strategy used by apoptotic cells for their removal. More recently, it has been determined that these Calr strategies are also used by a variety of other parasites. In addition, as reviewed elsewhere, TcCalr inhibits angiogenesis, promotes wound healing and reduces tumor growth. Complement C1 is also involved in some of these properties. Knowledge on the role of virulence factors, such as TcCalr, and their interactions with complement components in host-parasite interactions, may lead toward the description of new anti-parasite therapies and prophylaxis.
Patrocinador
University of Toledo Biomedical Research Innovation Program, Toledo, Ohio, USA
VID, University of Chile
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1130099
CONICYT-REDES
170126
Indexation
Artículo de publicación ISI Artículo de publicación SCOPUS
Quote Item
Frontiers in Immunology July 2020 | Volume 11 | Article 1561
Collections
The following license files are associated with this item: